Literature DB >> 24175669

Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Haiming Ding1, Michelle M Carlton, Stephen P Povoski, Keisha Milum, Krishan Kumar, Shankaran Kothandaraman, George H Hinkle, David Colcher, Rich Brody, Paul D Davis, Alex Pokora, Mitchell Phelps, Edward W Martin, Michael F Tweedle.   

Abstract

The tumor-associated glycoprotein-72 (TAG-72) antigen is highly overexpressed in various human adenocarcinomas and anti-TAG-72 monoclonal antibodies, and fragments are therefore useful as pharmaceutical targeting vectors. In this study, we investigated the effects of site-specific PEGylation with MW 2-4 kDa discrete, branched PEGylation reagents on mCC49 Fab' (MW 50 kDa) via in vitro TAG72 binding, and in vivo blood clearance kinetics, biodistribution, and mouse tumor microPET/CT imaging. mCC49Fab' (Fab'-NEM) was conjugated at a hinge region cysteine with maleimide-dPEG 12-(dPEG24COOH)3 acid (Mal-dPEG-A), maleimide-dPEG12-(dPEG12COOH)3 acid (Mal-dPEG-B), or maleimide-dPEG12-(m-dPEG24)3 (Mal-dPEG-C), and then radiolabeled with iodine-124 ((124)I) in vitro radioligand binding assays and in vivo studies used TAG-72 expressing LS174T human colon carcinoma cells and xenograft mouse tumors. Conjugation of mCC49Fab' with Mal-dPEG-A (Fab'-A) reduced the binding affinity of the non PEGylated Fab' by 30%; however, in vivo, Fab'-A significantly lengthened the blood retention vs Fab'-NEM (47.5 vs 28.1%/ID at 1 h, 25.1 vs 8.4%/ID at 5 h, p < 0.01), showed excellent tumor to background, better microPET/CT images due to higher tumor accumulation, and increased tumor concentration in excised tissues at 72 h by 130% (5.09 ± 0.83 vs 3.83 ± 1.50%ID/g, p < 0.05). Despite the strong similarity of the three PEGylation reagents, PEGylation with Mal-dPEG-B or -C reduced the in vitro binding affinity of Fab'-NEM by 70%, blood retention, microPET/CT imaging tumor signal intensity, and residual 72 h tumor concentration by 49% (3.83 ± 1.50 vs 1.97 ± 0.29%ID/g, p < 0.05) and 63% (3.83 ± 1.50 vs 1.42 ± 0.35%ID/g, p < 0.05), respectively. We conclude that remarkably subtle changes in the structure of the PEGylation reagent can create significantly altered biologic behavior. Further study is warranted of conjugates of the triple branched, negatively charged Mal-dPEG-A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24175669      PMCID: PMC4240220          DOI: 10.1021/bc400375f

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  57 in total

Review 1.  Effects of genetic engineering on the pharmacokinetics of antibodies.

Authors:  D Colcher; A Goel; G Pavlinkova; G Beresford; B Booth; S K Batra
Journal:  Q J Nucl Med       Date:  1999-06

2.  Staging of colorectal cancer: biology vs. morphology.

Authors:  M W Arnold; D M Young; C L Hitchcock; E Barberá-Guillem; C Nieroda; E W Martin
Journal:  Dis Colon Rectum       Date:  1998-12       Impact factor: 4.585

3.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.

Authors:  A Bendele; J Seely; C Richey; G Sennello; G Shopp
Journal:  Toxicol Sci       Date:  1998-04       Impact factor: 4.849

Review 4.  Polyethylene glycol modification: relevance of improved methodology to tumour targeting.

Authors:  G E Francis; C Delgado; D Fisher; F Malik; A K Agrawal
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

5.  Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.

Authors:  M E Schott; K A Frazier; D K Pollock; K M Verbanac
Journal:  Bioconjug Chem       Date:  1993 Mar-Apr       Impact factor: 4.774

6.  Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.

Authors:  C Abergel; E A Padlan; S V Kashmiri; D Milenic; B Calvo; J Schlom
Journal:  Proteins       Date:  1993-12

Review 7.  Pharmacokinetics and biodistribution of genetically-engineered antibodies.

Authors:  D Colcher; G Pavlinkova; G Beresford; B J Booth; A Choudhury; S K Batra
Journal:  Q J Nucl Med       Date:  1998-12

Review 8.  Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer.

Authors:  D J Bertsch; W E Burak; D C Young; M W Arnold; E W Martin
Journal:  Surgery       Date:  1995-10       Impact factor: 3.982

9.  Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging.

Authors:  M W Arnold; D C Young; C L Hitchcock; S Schneebaum; E W Martin
Journal:  Am J Surg       Date:  1995-10       Impact factor: 2.565

10.  The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.

Authors:  R B Pedley; J A Boden; R Boden; R H Begent; A Turner; A M Haines; D J King
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more
  6 in total

Review 1.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

Review 2.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 2: Peptide Tags and Unnatural Amino Acids.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

3.  Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.

Authors:  Shiv Ram Krishn; Sukhwinder Kaur; Lynette M Smith; Sonny L Johansson; Maneesh Jain; Asish Patel; Shailendra K Gautam; Michael A Hollingsworth; Ulla Mandel; Henrik Clausen; Wing-Cheong Lo; Wai-Tong Louis Fan; Upender Manne; Surinder K Batra
Journal:  Cancer Lett       Date:  2016-02-16       Impact factor: 8.679

4.  A 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic Colorectal Cancer Model.

Authors:  Li Gong; Haiming Ding; Nicholas E Long; Brandon J Sullivan; Edward W Martin; Thomas J Magliery; Michael F Tweedle
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

5.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

6.  Solid-phase bioconjugation of heterobifunctional adaptors for versatile assembly of bispecific targeting ligands.

Authors:  Hong Yan Liu; Pavel Zrazhevskiy; Xiaohu Gao
Journal:  Bioconjug Chem       Date:  2014-07-10       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.